





Certified Company

Certified Company

Date: 14-11-2024

National Stock Exchange of India Limited Exchange Plaza, C-1, Block G Bandra Kurla Complex, Bandra East, Mumbai-400051

Scrip Code: MUKKA

**BSE** Limited Listing Department Dalal Street, Mumbai-400001 Scrip Code: 544135

Dear Sir/Madam,

Subject: Statement of deviation(s) or variation(s) of funds raised through Initial Public offer ('IPO') for the quarter ended 30th September 2024.

Pursuant to Regulation 32(1) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the statement of deviation(s) or variation(s) in utilization of funds raised through IPO for the quarter ended 30th September 2024, duly reviewed by the Audit Committee at its meeting held today i.e., 14th November 2024, in the format prescribed by SEBI vide Circular No. CIR/CFD/CMD1/162/2019 dated December 24, 2019. Further, we confirm that there has been no deviation in the utilization of proceeds of IPO as mentioned in the objects stated in the Prospectus dated March 05, 2023.

The report issued by the Monitoring agency in this regard is being separately filed with the exchanges.

This is for your information and records.

Thank you,

For Mukka Proteins Limited

Mehaboobsab Mahmadgous Chalyal **Company Secretary & Compliance Officer** 

Encl: as above.

E-mail: info@mukkaproteins.com - Website: www.mukkaproteins.com - CIN: L05004KA2010PLC055771









Certified Company Certified Company

## Statement of Deviation / Variation in utilisation of funds raised

Name of listed entity	Mukka Proteins Limited
Mode of Fund Raising	Public Issues
Date of Raising Funds	Date of allotment - 06/03/2024
	Date of listing - 07/03/2024
Amount Raised	Rs. 2,240,000,000/-
Report filed for Quarter ended	30th September 2024
Monitoring Agency	Applicable
Monitoring Agency Name, if applicable	ICRA Limited
Is there a Deviation / Variation in use of funds raised	No
If yes, whether the same is pursuant to change in	Not Applicable
terms of a contract or objects, which was approved	
by the shareholders	
If Yes, Date of shareholder Approval	Not Applicable
Explanation for the Deviation / Variation	Not Applicable
Comments of the Audit Committee after review	Not Applicable
Comments of the auditors, if any	Not Applicable

## Objects for which funds have been raised and where there has been a deviation, in the following table:

Original	Modi	Original	Modifie	Funds	Amount of	Remark
Object	fied	Allocation (in	d	Utilised (in	Deviation/Variatio	s if any
	Obje	Rs.)	allocatio	Rs.)	n for the quarter	
	ct, if		n, if any		according to	
	any				applicable object	
Funding	NA	1,200,000,000	NA	1,200,000,000	NA	-
working						
capital						
requirements						
of our						
Company						
Investment	NA	100,000,000	NA	100,000,000	NA	-
in our						
Associate,						
viz. Ento						

## Mfrs. & Exporters of Steam Dried Fish Meal, Fish Oil & Fish Soluble Paste







ISO 22000 Certified Company

ISO 9001 : 2015 Certified Company

Proteins						
Private						
Limited,						
for funding						
its working						
capital						
requirements						
General	NA	558,080,000	NA	556,980,000	NA	-
corporate						
purposes^						

<sup>^</sup> The estimated IPO expenses as per the prospectus were Rs.38.192 crores, while the Actual IPO expenses have been higher by INR 7.428 crores and stood at INR 45.62 crores.

The estimated GCP utilization was capped at INR 50.910 crore in the last quarter due to excess issuer related expenses of Rs. 4.898 crores. However, in the current quarter the overall variance in IPO expenses of INR 7.428 crore including Rs. 2.53 of Issue related expenditure incurred in Q1 2025 has been absorbed into general corporate purpose.

## Deviation or variation could mean:

- (a) Deviation in the objects or purposes for which the funds have been raised or
- (b) Deviation in the amount of funds actually utilized as against what was originally disclosed or
- (c) Change in terms of a contract referred to in the fund-raising document i.e. prospectus, letter of offer, etc.

For Mukka Proteins Limited

Kalandan Mohammed Haris Managing Director & CEO DIN: 03020471 Kalandan Mohammed Althaf Whole-Time Director and CFO DIN: 03051103

E-mail: info@mukkaproteins.com - Website: www.mukkaproteins.com - CIN: L05004KA2010PLC055771